The antiviral agent 2′,3′-dideoxycytidine (ddC) has been shown to be active against HIV-1 infectivity. However, conflicting results have been reported concerning its efficacy in macrophages. Because macrophages possess low levels of the kinase(s) responsible for ddC phosphorylation, we investigated the ability of ddC and 2′,3′-dideoxycytidine 5′-trisphosphate (ddCTP) to suppress HIV-1 and LP-BM5 replication in these cells. Retrovirus replication was only partially inhibited in the two systems investigated by a high (1 μM) ddC concentration. The direct administration of ddCTP, using autologous red blood cells as a delivery system, was found to inhibit HIV-1 and LP-BM5 replication by more than 90% in macrophages without affecting major cell functions. These data, together with those already reported for FIV [Magnani et al. (1994) AIDS Res Hum Retroviruses 10: 1179-1186], suggest that the anabolic phosphorylation of ddC is an important determinant of its anti-HIV activity and that pharmacological interventions that modulate ddC metabolism may be useful for improving its antiretroviral activity in macrophages.
ArnérE.S., and ErikssonS. (1993) Deoxycytidine and 2′,3′-dideoxycytidine metabolism in human monocyte-derived macrophages. A study of both anabolic and catabolic pathways. Biochem Biophys Res Commun197: 1499–1504.
2.
ArnérE.S.ValentinA., and ErikssonS. (1992) Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J Biol Chem267: 10968–10975.
3.
AzizD.C.HannaZ., and JolicoeurP. (1989) Severe immunodeficiency disease induced by a defective murine leukemia virus. Nature338: 505–508.
4.
BalzariniJ.PauwelsR.BabaM.HerdewijnP.De ClercqE.BroderS., and JohnsD.G. (1988) The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell specis. Biochem Pharmacol37: 893–903.
5.
Barré-SinoussiF.ChermannJ.C.ReyF.NugeyreM.T.ChamaretS.GruestJ.DaugetC.Axler-BlinC.VezinetF.RonziouxC.RozenbaumW., and MontagnierL. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science220: 868–871.
6.
BergerA.R.ArezzoJ.C.SchanmburgH.H.SkowronG.MeriganT.BozzettaS.RichmanD., and SooW. (1993) 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology43: 358–362.
7.
BilelloJ.A.KortJ.J.MacAullyC.FredricksonT.M.YetterR.A., and EisemanJ.L. (1992) ZDV delay but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytes. J AIDS5: 571–576.
8.
ChattopadhyayS.K.SenguptaD.N.FredricksonT.N.MorseH.C.III, and HartleyJ.W. (1991) Characteristic and contributions of defective, ecotropic and mink cell focus-inducing viruses induced in a retrovirus induced immunodeficiency syndrome of mice. J Virol65: 4232–4241.
9.
ChenC.H., and ChengY.C. (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem264: 11934–11937.
10.
De ClercqE. (1991) Basic approaches to anti-retroviral treatment. J. AIDS4: 207–218.
11.
GaoW.CaraA.GalloR., and LoriF. (1993) Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA90: 8925–8928.
12.
GaoW.AgbariaR.DriscollJ.S., and MitsuyaH. (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem269: 12633–12638.
13.
HirschM.S., and D'AquilaR.T. (1993) Therapy for human immunodeficiency virus infection. N Engl J Med328: 1686–1695.
14.
KellogD., and KwokS. (1990) Detection of human immunodeficiency virus. In PCR Protocols. A guide to Methods and Applications. InnisM.A.GelfandD.H.SninskyJ.J., and WhiteT.J., eds. San Diego, CA: Academic Press, pp. 337–347.
15.
Kurdi-HaidarB.MasonP.J.BerrebiA.Ankra-BoduG.Al-AlìA.OppemheimA., and LuzzattoL. (1990) Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet47: 1013–1019.
16.
MagnaniM.RossiL.BrandiG.SchiavanoG.F.MontroniM., and PiedimonteG. (1992) Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA89: 6477–6481.
17.
MagnaniM.RossiL.FraternaleA.SilvottiL.QuintavallaF.PiedimonteG.MatteucciD.BaldinottiF., and BendinelliM. (1994) Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by ddCTP-loaded erythrocytes. AIDS Res Hum Retroviruses10: 1179–1186.
18.
MeltzerM.S.SkillmanD.R.HooverV.L.HausonB.D.TurpinJ.A.KalterD.C., and SendelmanH.E. (1990) Macrophages and the human immunodeficiency virus. Immunol Today11: 217–223.
19.
MeyerhansA.VartanianJ.P.HultgrenC.PlikatU.KarlssonA.WangL.ErikssonS., and Wain-HobsonS. (1994) Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol68: 535–540.
20.
MitsujaH.YarchoanR., and BroderS. (1990) Molecular targets for AIDS therapy. Science249: 1593–1544.
21.
MosierD.E.YetterR.A., and MorseH.C.III (1987) Functional T lymphocytes are required for a murine retrovirus induced immunodeficiency disease (MAIDS). J Exp Med165: 1737–1742.
22.
NorthT.W.NorthG.T., and PedersenN.C. (1989) Feline immunodeficiency virus, a model for reverse transcriptase chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother33: 915–919.
23.
NorthT.W.CronnR.C.RemingtonK.M., and TandbergR.T. (1990) Direct comparison of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemiother34: 1505–1507.
24.
OuC.Y.KwokS.MitchellS.W.HackD.H.SninskyJ.J.KrebsJ.W.FeorinoP.WarfieldD.ShochetmanG. (1988) DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science236: 295–297.
25.
PernoC.F.YarchoanR.CooneyD.A.HartmanN.R.GartnerS.PopovicM.HaoZ.GerrardT.L.WilsonY.A.JohnsD.G., and BroderS. (1988) Inhibition of human immunodeficiency virus (HIV-1/HTLV-III BA-L) replication in fresh and cultured human peripheral blood monocyte/ macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med168: 1111–1125.
26.
PickE. (1986) Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using an enzyme immunoassay microplate reader. Methods Enzymol132: 407–421.
27.
PiedimonteG.MontroniM.SilvestriG.SilvottiL.DonatiniA.RossiL.BorghettiA.F., and MagnaniM. (1993) Phagocytosis reduces HIV-1 production in human monocyte/ macrophages infected in vitro. Arch Virol130: 63–469.
28.
RichmanD.D.KornblluthR.S., and CarsonD.A. (1987) Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med166: 144–1149.
29.
RossiL.BrandiG.SchiavanoG.F.ChiarantiniL.AlbanoA., and MagnaniM. (1992) In vitro and in vivo toxicity of 2′,3′-dideoxycytidine in mice. Chem Biol Interactions85: 55–263.
30.
RossiL.BrandiG.FraternaleA.SchiavanoG.F.ChiarantiniL., and MagnaniM. (1993). Inhibition of murine-retrovirus induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′-triphosphate. J AIDS6: 1179–1186.
31.
SambrookJ.FritschE.F., and ManiatisF. (eds) (1989). Molecular Cloning: A Laboratory Manual, 2nd edn.New York: Cold Spring Harbor Laboratory Press, pp. 1131–1133.
32.
Wain-HobsonS.VartanianJ.P.HenryM.ChencinerN.CheynierR.DelassusS.MartinsL.P.SalaM.NugeyreM.T.GuétardD.KlarzmannD.GluckmanJ.C.RozenbaumW.Barré-SinoussiF., and MontagnierL. (1991) LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science252: 961–965.
